GPX4 and polycystic ovary syndrome: Thorough, prospective studies are crucial to validate promising biomarkers such as glutathione, malondialdehyde, ORP, and GPX4 activity, as well as to evaluate targeted medications in specifically defined patient populations, including women with PCOS, reduced ovarian reserve, and endometriosis.